Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value Measurements [Abstract]

Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis



Fair Value Measurements at March 31, 2018
	Total		Level 1		Level 2		Level 3
Assets:
Commercial Paper		1,245,263		-		1,245,263		-
Corporate Bonds		13,639,281		-		13,639,281		-
Total Assets:	$	14,884,544	$	-	$	14,884,544	$	-

Liabilities:
Warrant Liabilities	$	4,487,139	$	-	$	-	$	4,487,139


Fair Value Measurements at December 31, 2017
	Total		Level 1		Level 2		Level 3
Assets:
Commercial Paper		3,238,500		-		3,238,500		-
Corporate Bonds		14,693,441		-		14,693,441		-
Total Assets:	$	17,931,941	$	-	$	17,931,941	$	-

Liabilities:
Warrant Liabilities	$	7,853,635	$	-	$	-	$	7,853,635

Reconciliation Of Changes In The Fair Value Of Liabilities



		Warrant Liabilities
Balance at January 1, 2018		$	7,853,635
Additions			-
Unrealized gains, net			(3,366,496)
Transfers out of level 3			-
Balance at March 31, 2018		$	4,487,139



		Warrant Liabilities
Balance at January 1, 2017		$	1,573,366
Additions			-
Unrealized losses, net			17,689,580
Transfers out of level 3			(3,029,115)
Balance at March 31, 2017		$	16,233,831